Now showing items 1-10 of 12
Cost of innovation in the pharmaceutical industry.
(J Health Econ, 1991-07)
The research and development costs of 93 randomly selected new chemical entities (NCEs) were obtained from a survey of 12 U.S.-owned pharmaceutical firms. These data were used to estimate the pre-tax average cost of new ...
R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
(International Journal of the Economics of Business, 1995-01-01)
This study examines the relationships between firm size, R&D costs and output in the pharmaceutical industry. Project-level data from a survey of 12 US-owned pharmaceutical firms on drug development costs, development phase ...
The cost of biopharmaceutical R&D: Is biotech different?
(Managerial and Decision Economics, 2007-06-01)
The costs of developing the types of new drugs that have been pursued by traditional pharmaceutical firms have been estimated in a number of studies. However, similar analyses have not been published on the costs of developing ...
Should the patent system for new medicines be abolished?
(Clin Pharmacol Ther, 2007-11)
Innovation in the pharmaceutical industry: New estimates of R&D costs.
(J Health Econ, 2016-05)
The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug and biologics development. ...
The price of innovation: new estimates of drug development costs.
(J Health Econ, 2003-03)
The research and development costs of 68 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug development. The costs of ...
Returns on R&D for 1990s New Drug Introductions
The roles of patents and research and development incentives in biopharmaceutical innovation.
(Health Aff (Millwood), 2015-02)
Patents and other forms of intellectual property protection play essential roles in encouraging innovation in biopharmaceuticals. As part of the "21st Century Cures" initiative, Congress is reviewing the policy mechanisms ...
The cost of drug development.
(N Engl J Med, 2015-05-14)
Economics of new oncology drug development.
(J Clin Oncol, 2007-01-10)
PURPOSE: Review existing studies and provide new results on the development, regulatory, and market aspects of new oncology drug development. METHODS: We utilized data from the US Food and Drug Administration (FDA), company ...